A new type of antibiotic may help millions of COPD patients and children with middle ear infections. The drug is unlikely to have any side effects and has the great advantage that no resistance development can occur. Researchers from Radboud university medical center and Radboud University presented their initial results this week in Cell Chemical Biology.